Peking University Cancer Hospital & Institute: Melanoma trials

The registry lists 31 Melanoma studies with Peking University Cancer Hospital & Institute as lead sponsor. 8 are open to participants now and 0 have results posted.

Phase 1 7Phase 2 18Phase 3 2Phase 4 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral MelanomaNot yet recruitingNCT07854522Phase 4
• Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide ProbesRecruitingNCT07848243Phase 2
• PD-L1 Targeting Peptide Probe for PET Imaging of Solid TumorNot yet recruitingNCT07442292
• A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal MelanomaEnrolling by invitationNCT06424626Phase 1
• Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral MelanomaRecruitingNCT05789043Phase 3
• Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral MelanomaRecruitingNCT05512481Phase 2
• Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced MelanomaRecruitingNCT05478473Not applicable
• Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II StudyRecruitingNCT04462965Phase 2
• Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT MutStatus unknownNCT05274438Phase 2
• PD-L1 Targeting Nanobody Probe for PET Imaging of Solid TumorStatus unknownNCT05156515Not applicable
• Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic MelanomaStatus unknownNCT05104801Phase 2
• Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver MetastasisStatus unknownNCT05070221Phase 1
• Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver MetastasisStatus unknownNCT05068453Phase 1
• To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced MelanomaStatus unknownNCT05051865Phase 2
• Lenvatinib and Pembrolizumab in Resectable Mucosal MelanomaStatus unknownNCT04622566Phase 2
• Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral MelanomaStatus unknownNCT04397770Phase 2
• The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of MelanomaStatus unknownNCT04357509Phase 1
• Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From MelanomaStatus unknownNCT04206358Phase 1
• Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced MelanomaActive, not recruitingNCT04197882Phase 1
• Toripalimab in Combination With Axitinib in Patients With Localized Mucosal MelanomaStatus unknownNCT04180995Phase 2
• PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral MelanomaStatus unknownNCT03955354Phase 2
• Phase II Study in the Treatment of Patients With Advanced Mucinous MelanomaStatus unknownNCT03941795Phase 2
• Nab-PCE vs PC for MM After Failure of Anti-PD-1Status unknownNCT03917069Phase 2
• Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene AberrationsStatus unknownNCT03454919Phase 2
• HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal MelanomaStatus unknownNCT03435302Phase 3
• A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced MelanomaStatus unknownNCT03422445Phase 2
• Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic MelanomaStatus unknownNCT03095079Phase 2
• A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma PatientsStatus unknownNCT02619058Phase 1
• Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal MelanomaStatus unknownNCT02023710Phase 2
• Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety StudyStatus unknownNCT01960829Phase 2
• A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated MelanomaStatus unknownNCT01782508Phase 2